MX2016010781A - Composiciones para la inactivacion de la replicacion de virus y metodos de fabricacion y uso de las mismas. - Google Patents
Composiciones para la inactivacion de la replicacion de virus y metodos de fabricacion y uso de las mismas.Info
- Publication number
- MX2016010781A MX2016010781A MX2016010781A MX2016010781A MX2016010781A MX 2016010781 A MX2016010781 A MX 2016010781A MX 2016010781 A MX2016010781 A MX 2016010781A MX 2016010781 A MX2016010781 A MX 2016010781A MX 2016010781 A MX2016010781 A MX 2016010781A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- target sequence
- trna
- polynucleotide encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan construcciones recombinantes, vectores y casetes de expresión que incluyen un primer promotor que, convenientemente, es un promotor de ARNt conectado operativamente a un primer polinucleótido que codifica un primer ARN guía único y un segundo promotor conectado operativamente a un segundo polinucleótido que codifica un polipéptido Cas9. El primer ARN guía único incluye una primera parte complementaria a una cadena de una secuencia diana de un virus de ADN y una segunda parte capaz de interaccionar con el polipéptido Cas9. También se proporcionan polipéptidos y polinucleótidos de Cas9 obtenidos de Staphylococcus aureus de codones optimizados con señales de localización nuclear y opcionalmente un marcador de epítopo. También se proporcionan construcciones para la producción de ARNsg que incluyen un ARNt. También se proporcionan métodos para inhibir la replicación viral, inhibir la expresión de una secuencia diana procedente de un virus o tratar una infección vírica o un cáncer inducido por virus usando las composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461940883P | 2014-02-18 | 2014-02-18 | |
PCT/US2015/016354 WO2015126927A2 (en) | 2014-02-18 | 2015-02-18 | Compositions for the inactivation of virus replication and methods of making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010781A true MX2016010781A (es) | 2017-02-15 |
Family
ID=53879230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010781A MX2016010781A (es) | 2014-02-18 | 2015-02-18 | Composiciones para la inactivacion de la replicacion de virus y metodos de fabricacion y uso de las mismas. |
Country Status (14)
Country | Link |
---|---|
US (2) | US10286084B2 (es) |
EP (1) | EP3107999A4 (es) |
JP (1) | JP2017506893A (es) |
KR (1) | KR20160130392A (es) |
CN (1) | CN106232823A (es) |
AU (1) | AU2015219167A1 (es) |
BR (1) | BR112016019068A2 (es) |
CA (1) | CA2940084A1 (es) |
IL (1) | IL247309A0 (es) |
MX (1) | MX2016010781A (es) |
PH (1) | PH12016501623A1 (es) |
RU (1) | RU2016136977A (es) |
SG (1) | SG11201606819QA (es) |
WO (1) | WO2015126927A2 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
CN111218447A (zh) | 2013-11-07 | 2020-06-02 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
WO2015183667A1 (en) * | 2014-05-28 | 2015-12-03 | The Regents Of The University Of California | HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE |
US20160060655A1 (en) * | 2014-05-30 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
MA41349A (fr) * | 2015-01-14 | 2017-11-21 | Univ Temple | Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn |
JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
JP2018516984A (ja) * | 2015-05-29 | 2018-06-28 | アジェノビア コーポレーション | 細胞を標的にしたhpv処置のための組成物および方法 |
US10117911B2 (en) * | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US20180245074A1 (en) * | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
WO2016197133A1 (en) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics, Inc. | Delivering crispr therapeutics with lipid nanoparticles |
EP3325018A4 (en) | 2015-07-22 | 2019-04-24 | Duke University | HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES |
ES2929110T3 (es) | 2015-08-25 | 2022-11-24 | Univ Duke | Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN |
EP3356528A4 (en) * | 2015-09-29 | 2019-08-28 | Agenovir Corporation | COMPOSITIONS AND METHODS FOR REGULATING LATENT VIRAL TRANSCRIPTION |
WO2017058793A1 (en) * | 2015-09-29 | 2017-04-06 | Agenovir Corporation | Delivery methods and compositions |
US20170088828A1 (en) * | 2015-09-29 | 2017-03-30 | Agenovir Corporation | Compositions and methods for treatment of latent viral infections |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
US20190225955A1 (en) | 2015-10-23 | 2019-07-25 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
EP3368670A1 (en) * | 2015-10-30 | 2018-09-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
EP3708665A1 (en) * | 2015-12-18 | 2020-09-16 | Danisco US Inc. | Methods and compositions for t-rna based guide rna expression |
AU2017371665A1 (en) * | 2016-01-25 | 2018-07-19 | Excision Biotherapeutics | RNA guided eradication of human JC virus and other polyomaviruses |
EP3443081A4 (en) * | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3463406A4 (en) * | 2016-06-01 | 2020-01-22 | Excision Biotherapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT AGAINST LYTIC AND LYSOGENIC VIRUSES |
AU2017277810A1 (en) * | 2016-06-03 | 2018-12-06 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of HIV-1 by gene editing strategy |
US11351273B2 (en) | 2016-06-21 | 2022-06-07 | Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College | Method for delivering RNA to neurons to treat herpes infections |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
EP3532616A1 (en) | 2016-10-28 | 2019-09-04 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
KR102489902B1 (ko) * | 2016-11-11 | 2023-01-19 | 바이오 래드 래버러토리스 인코오포레이티드 | 핵산 샘플을 프로세싱하는 방법 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11674138B2 (en) | 2017-03-13 | 2023-06-13 | President And Fellows Of Harvard College | Methods of modulating expression of target nucleic acid sequences in a cell |
EP3600382A4 (en) * | 2017-03-21 | 2020-12-30 | Anthony P. Shuber | TREATMENT OF CANCER WITH CAS ENDONUCLEASE COMPLEXES |
IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
EP3601568A1 (en) * | 2017-03-31 | 2020-02-05 | Agenovir Corporation | Antiviral therapeutic |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | LIPID NANOPARTICLE MEDIA ADMINISTRATION OF PLASMIDIC DNA EXPRESSING CRISPR FOR THE TREATMENT OF CHRONIC INFECTION WITH HEPATITIS B VIRUS |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
WO2019024081A1 (zh) | 2017-08-04 | 2019-02-07 | 北京大学 | 特异性识别甲基化修饰dna碱基的tale rvd及其应用 |
JP7109009B2 (ja) | 2017-08-08 | 2022-07-29 | 北京大学 | 遺伝子ノックアウト方法 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
CN109468319A (zh) * | 2017-09-08 | 2019-03-15 | 中山大学 | 用于抑制HSV-1复制和/或靶标序列表达的CRISPR/Cas9***、方法、试剂盒及其应用 |
CN109468318A (zh) * | 2017-09-08 | 2019-03-15 | 中山大学 | 用于抑制HSV-1复制和/或靶标序列表达的CRISPR/Cas9***、方法、试剂盒及其应用 |
CN107557394A (zh) * | 2017-09-29 | 2018-01-09 | 南京鼓楼医院 | 降低CRISPR/Cas9介导的胚胎基因编辑脱靶率的方法 |
EP3697906A1 (en) | 2017-10-16 | 2020-08-26 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP3697916A4 (en) | 2017-10-20 | 2021-08-11 | Research Institute at Nationwide Children's Hospital | METHODS AND MATERIALS FOR NT-3 GENE THERAPY |
WO2019152868A1 (en) * | 2018-02-01 | 2019-08-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus (hsv) related keratitis |
WO2019184655A1 (zh) * | 2018-03-27 | 2019-10-03 | 苏州克睿基因生物科技有限公司 | CRISPR/Cas***在基因编辑中的应用 |
CN112088215A (zh) * | 2018-05-09 | 2020-12-15 | 帝斯曼知识产权资产管理有限公司 | Crispr瞬时表达构建体(ctec) |
CN113646434B (zh) * | 2018-12-20 | 2023-05-30 | 北京大学 | 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法 |
CN111349654B (zh) * | 2018-12-20 | 2023-01-24 | 北京大学 | 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法 |
US20220110963A1 (en) * | 2019-01-02 | 2022-04-14 | The General Hospital Corporation | Reverse transcriptase blocking agents and methods of using the same |
EP3918071A1 (en) * | 2019-02-01 | 2021-12-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions targeting virus genomes |
MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
KR20200123392A (ko) * | 2019-04-18 | 2020-10-29 | 주식회사 툴젠 | B형 간염 바이러스의 증식을 억제하는 조성물 및 이의 방법 |
CN111139240B (zh) * | 2020-01-20 | 2022-03-15 | 武汉大学 | 一种靶向乙型肝炎病毒的改造的CRISPR/SaCas9***及其应用 |
WO2021178924A1 (en) * | 2020-03-05 | 2021-09-10 | Board Of Regents Of The University Of Nebraska | Crispr/cas9 system for multistrain hiv-1 treatment |
JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート,インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
WO2024119102A1 (en) * | 2022-12-01 | 2024-06-06 | Locanabio, Inc. | Adeno-associated viral vectors for proper packaging of repetitive elements |
WO2024124416A1 (en) * | 2022-12-14 | 2024-06-20 | Wuhan Institute Of Virology, Chinese Academy Of Sciences | Engineered murine cytomegalovirus-derived tool virus, method of producing the same and applications thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
US20080318210A1 (en) | 2003-08-27 | 2008-12-25 | Rosetta Genomics | Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof |
WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
US7795419B2 (en) | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
RU2007135164A (ru) * | 2005-02-23 | 2009-03-27 | Эйдженси Фор Сайенс, Текнолоджи Энд Рисерч (Sg) | Иммортализованные фидерные клетки |
US20080193563A1 (en) | 2006-08-01 | 2008-08-14 | Rush University Medical Center | Harnessing wnt signaling to restrict hiv replication |
WO2009006584A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Colorado | Methods and compositions for identifying cellular rna transcripts |
US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
WO2012006551A2 (en) * | 2010-07-08 | 2012-01-12 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
EP2694685B1 (en) | 2011-04-08 | 2019-01-09 | Azzazy, Hassan, Mohamed, Ei-said | Detection of nucleic acids using unmodified gold nanoparticles |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
UA118014C2 (uk) * | 2012-05-25 | 2018-11-12 | Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія | Спосіб модифікації днк-мішені |
CN110669746B (zh) | 2012-10-23 | 2024-04-16 | 基因工具股份有限公司 | 用于切割靶dna的组合物及其用途 |
IL300199A (en) | 2012-12-06 | 2023-03-01 | Sigma Aldrich Co Llc | CRISPR-based genome modification and regulation |
DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
RU2721275C2 (ru) | 2012-12-12 | 2020-05-18 | Те Брод Инститьют, Инк. | Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии |
DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
CA2894668A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells |
PL2921557T3 (pl) | 2012-12-12 | 2017-03-31 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
SG10201912327SA (en) * | 2012-12-12 | 2020-02-27 | Broad Inst Inc | Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation |
CN103233028B (zh) * | 2013-01-25 | 2015-05-13 | 南京徇齐生物技术有限公司 | 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列 |
WO2014140347A2 (en) * | 2013-03-15 | 2014-09-18 | Allozyne, Inc | Novel nucleic acid molecules |
KR20160060659A (ko) * | 2013-08-29 | 2016-05-30 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물 |
AU2014361784A1 (en) * | 2013-12-12 | 2016-06-23 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders |
EP3207139A1 (en) * | 2014-10-17 | 2017-08-23 | The Penn State Research Foundation | Methods and compositions for multiplex rna guided genome editing and other rna technologies |
-
2015
- 2015-02-18 CN CN201580017543.7A patent/CN106232823A/zh active Pending
- 2015-02-18 AU AU2015219167A patent/AU2015219167A1/en not_active Abandoned
- 2015-02-18 BR BR112016019068A patent/BR112016019068A2/pt not_active Application Discontinuation
- 2015-02-18 WO PCT/US2015/016354 patent/WO2015126927A2/en active Application Filing
- 2015-02-18 SG SG11201606819QA patent/SG11201606819QA/en unknown
- 2015-02-18 JP JP2016552891A patent/JP2017506893A/ja active Pending
- 2015-02-18 RU RU2016136977A patent/RU2016136977A/ru not_active Application Discontinuation
- 2015-02-18 MX MX2016010781A patent/MX2016010781A/es unknown
- 2015-02-18 US US15/119,867 patent/US10286084B2/en active Active
- 2015-02-18 KR KR1020167024987A patent/KR20160130392A/ko unknown
- 2015-02-18 CA CA2940084A patent/CA2940084A1/en not_active Abandoned
- 2015-02-18 EP EP15751819.2A patent/EP3107999A4/en not_active Withdrawn
-
2016
- 2016-08-15 PH PH12016501623A patent/PH12016501623A1/en unknown
- 2016-08-17 IL IL247309A patent/IL247309A0/en unknown
-
2019
- 2019-05-10 US US16/409,406 patent/US20190351070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12016501623A1 (en) | 2016-11-07 |
US20170049909A1 (en) | 2017-02-23 |
WO2015126927A3 (en) | 2015-11-19 |
US10286084B2 (en) | 2019-05-14 |
BR112016019068A2 (pt) | 2017-10-10 |
US20190351070A1 (en) | 2019-11-21 |
EP3107999A4 (en) | 2017-10-04 |
SG11201606819QA (en) | 2016-09-29 |
KR20160130392A (ko) | 2016-11-11 |
AU2015219167A1 (en) | 2016-09-08 |
EP3107999A2 (en) | 2016-12-28 |
IL247309A0 (en) | 2016-09-29 |
RU2016136977A (ru) | 2018-03-20 |
WO2015126927A2 (en) | 2015-08-27 |
AU2015219167A2 (en) | 2017-04-13 |
CA2940084A1 (en) | 2015-08-27 |
JP2017506893A (ja) | 2017-03-16 |
CN106232823A (zh) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501623A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
MX2020003526A (es) | Una plataforma universal para la preparación de un receptor antigénico quimérico inhibidor (icar). | |
MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
MX2017006652A (es) | Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central. | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
WO2018136396A3 (en) | Crisprs | |
MX2023001834A (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. | |
WO2015191666A3 (en) | Raf1 fusions | |
EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
MX2019001672A (es) | Composiciones de poxvirus quiméricos y usos de las mismas. | |
BR112018015659A2 (pt) | genes otimizados do fator viii | |
MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
MX2017016101A (es) | Polinucleotidos y polipetidos de adenovirus. | |
MX2018005145A (es) | Terapia genetica. | |
MX2021001460A (es) | Metodos y composiciones para secrecion de polipeptidos heterologos. | |
WO2015181119A3 (en) | Lipase variants and polynucleotides encoding same | |
MX2021013879A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
MX2017007105A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
WO2018069947A8 (en) | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine | |
AR101146A1 (es) | Proteína con actividad xilanasa |